AstraZeneca sells Atacand rights to Cheplapharm for $400m

Fri, 30th Oct 2020 07:23

(Sharecast News) - AstraZeneca said it was selling the commercial rights to its heart failure and hypertension drug Atacand and Atacand Plus in around 70 countries globally to Cheplapharm Arzneimittel for $400m.
The deal is expected to complete in the final quarter of 2020, AstraZeneca said on Friday, adding that $250m of the purchase price would be payable on completion and the rest in the first half of 2021.

.

Related Shares

More News

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...